Treatment Patterns Following Discontinuation of Adalimumab, Etanercept, and Infliximab in a US Managed Care Sample

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis

Kenneth G. Saag, Gim Gee Teng, Nivedita M. Patkar et al. · Arthritis Care & Research · 2008 · 1.5K citations

Orthopedic Physical Therapy, Pharmacotherapy, Inflammatory Arthritis +20

Guidelines for the management of rheumatoid arthritis: 2002 Update

Arthritis & Rheumatism · 2002 · 1.2K citations

Rheumatoid Disorder, Rheumatology, Rheumatic Diseases +4

Guidelines for the management of rheumatoid arthritis: 2002 Update

Robert A. Yood · 2002 · 1.1K citations

Rheumatoid Disorder, Rheumatology, Rheumatic Diseases +4

Guidelines for the Management of Rheumatoid Arthritis 2002 Update

Mary Jo Goolsby, Grace Newsome · Journal of the American Academy of Nurse Practitioners · 2002 · 859 citations

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

Merete Lund Hetland, Ib Jarle Christensen, Ulrik Tarp et al. · Arthritis & Rheumatism · 2009 · 529 citations